Last updated: March 2, 2026
What Is the Drug Associated with NDC 60846-0809?
The National Drug Code (NDC) 60846-0809 corresponds to DaxibotulinumtoxinA-lanm (Daxxify). Daxxify is a long-acting botulinum toxin engineered for the treatment of glabellar lines (frown lines) and other aesthetic indications. It is developed by Revance Therapeutics.
Current Market Position
Revance launched Daxxify in late 2022 following FDA approval in 2022. The drug offers up to 6-9 months of wrinkle reduction, surpassing traditional botulinum toxins like Botox, which generally last 3-4 months.
Market Share and Competitive Landscape
-
Market size: The aesthetic neuromodulator market was valued at approximately $4.8 billion in 2022, with Botox comprising roughly 70-80% of market share.
-
Competitors:
- Botox (AbbVie)
- Dysport (Ipsen/Galderma)
- Jeuveau (Evolus)
- Xeomin (Eli Lilly)
- Daxxify (Revance)
-
Daxxify's advantage: Longevity of effect positions it as a premium product with potential for higher pricing.
-
Market penetration: Initial adoption remains cautious, with rollout concentrated in high-income regions. Expected steady growth as physicians gain familiarity and confidence.
Regulatory and Reimbursement Factors
- Regulatory status: FDA approval received in October 2022. Market launch began in late 2022.
- Reimbursement landscape: Reimbursement codes established; coverage depends on payer policies, with most private insurers adopting initial coverage. Medicare coverage is under review, which could influence adoption rates.
Supply Chain and Manufacturing
- Revance employs a proprietary manufacturing process, allowing for scalable production.
- Supply chain disruptions are limited but could impact pricing if demand surges faster than production capacity.
Price Projections
Price Benchmarking
- Current retail price: Approximately $1,200–$1,400 per 100 units (vial size standard for aesthetic indications). This is higher than Botox, which ranges from $500–$600 per 100 units.
- Pricing rationale: Longer duration justifies premium pricing. Market launch prices may initially be at the higher end of this spectrum.
Short-term Price Outlook (2023-2024)
- Price stability: Expect minimal decreases due to early shipping costs and premium positioning.
- Potential for increases: Slight price hikes of 3–5% annually are plausible if demand exceeds supply or if manufacturing costs rise.
- Pricing pressure factors:
- Competition entry offers a route for price reductions.
- Payer negotiations could lead to discounts, especially with increasing formulary tiers.
Long-term Price Trends (2025–2030)
- Market penetration effects: Growing adoption and increased competition could lower prices by 10–20%, aligning it more closely with existing botulinum products.
- Economies of scale: Expansion of manufacturing capacity could decrease cost per unit, enabling potential downward price adjustments.
- Emerging indications: Expansion into therapeutic uses might introduce new pricing strategies, potentially with higher price points.
Revenue Projections
| Year |
Estimated Units Sold |
Average Price per 100 Units |
Revenue Projection |
Notes |
| 2023 |
1 million units |
$1,300 |
$13 million |
Initial rollout in key markets. |
| 2024 |
2 million units |
$1,300 |
$26 million |
Increased adoption and expanded provider base. |
| 2025 |
3.5 million units |
$1,200–$1,300 |
$42–$45 million |
Market expansion; price adjustments possible. |
| 2030 |
6 million units |
$1,000–$1,200 |
$60–$72 million |
Broader use cases; price pressures and increased competition. |
Key Factors Influencing Market and Pricing
- Clinical efficacy: Longer-lasting effects set Daxxify apart, enabling premium pricing.
- Physician adoption: Influenced by safety profile, ease of use, and peer acceptance.
- Reimbursement policies: Coverage levels impacting patient access and willingness to pay.
- Competition entry: New entrants with similar longevity could suppress prices.
- Regulatory approvals: Expansion into therapeutic indications may increase volume but affect pricing strategies.
Summary
Daxxify's market entry presents opportunities for premium pricing driven by its extended duration. Early adoption remains cautious but is expected to grow, supported by favorable reimbursement and clinical advantages. Over the next five years, prices are likely to trend downward as competition and market penetration increase, with long-term revenues potentially reaching $70 million annually by 2030.
Key Takeaways
- Daxxify, approved in 2022, targets a niche for longer-lasting botulinum toxin treatments.
- Initial prices are approximately $1,200–$1,400 per 100 units.
- Revenue growth is projected to be robust, reaching $60–$72 million by 2030.
- Competition and reimbursement adjustments will influence pricing.
- Market penetration depends heavily on physician acceptance and patient demand.
FAQs
1. What are the main factors affecting Daxxify’s market adoption?
Physician familiarity, reimbursement landscape, pricing strategies, and competition from established botulinum toxins.
2. How does Daxxify’s pricing compare with Botox?
It is typically priced 2–3 times higher per 100 units, justified by its longer duration of effect.
3. Will prices decrease significantly in the future?
Yes, as competition increases and market penetration deepens, prices are likely to decrease by 10–20% over several years.
4. How are reimbursement policies expected to impact Daxxify?
Coverage limitations could restrict patient access initially; expanded coverage will facilitate higher utilization and revenue.
5. What therapeutic indications could expand Daxxify’s market?
Beyond aesthetic uses, its longer duration could make it suitable for various muscle spasm and dystonia treatments, potentially increasing sales volume.
References
- Revance Therapeutics. (2022). Daxxify (DaxibotulinumtoxinA-lanm) Prescribing Information.
- Grand View Research. (2023). Botulinum Toxin Market Size, Share & Trends.
- IQVIA. (2023). Pharmaceutical Market Data for Aesthetic Treatments.
- Center for Drug Evaluation and Research (CDER). (2022). FDA Approval Documents for Daxxify.
- Dun & Bradstreet. (2023). Market Demand and Competitive Analysis for Neurotoxins.
